We are live on ! Find out more
CRSP icon

CRISPR Therapeutics
CRSP

174 hedge funds and large institutions have $1.09B invested in CRISPR Therapeutics in 2018 Q2 according to their latest regulatory filings, with 70 funds opening new positions, 52 increasing their positions, 32 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more first-time investments, than exits

New positions opened: 70 | Existing positions closed: 30

63% more repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 32

29% more funds holding

Funds holding: 135 → 174 (+39)

27% more capital invested

Capital invested by funds: $855M → $1.09B (+$232M)

0.64% less ownership

Funds ownership: 39.84% → 39.2% (-0.64%)

20% less funds holding in top 10

Funds holding in top 10: 5 → 4 (-1)

66% less call options, than puts

Call options by funds: $29.7M | Put options by funds: $86.8M

Holders
174
Holders Change
+39
Holders Change %
+28.89%
% of All Funds
3.98%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.09%
New
70
Increased
52
Reduced
32
Closed
30
Calls
$29.7M
Puts
$86.8M
Net Calls
-$57.1M
Net Calls Change
-$35.1M

Top Buyers

1
Federated Hermes
Federated Hermes
Pennsylvania
+$36M
2
AIM
ARK Investment Management
Florida
+$22.5M
3
O
OrbiMed
New York
+$22.3M
4
Two Sigma Advisers
Two Sigma Advisers
New York
+$19M
5
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$12.9M

Top Sellers

1
NMC
NEA Management Company
Maryland
-$79.4M
2
VVM
Versant Venture Management
California
-$56.8M
3
A
Abingworth
United Kingdom
-$37M
4
MWNA
Marshall Wace North America
New York
-$21.8M
5
NHAS
Novo Holdings A/S
Denmark
-$10.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
EIM
51
Essex Investment Management
Massachusetts
$2.41M +$1.09M +19,149 +88%
Victory Capital Management
52
Victory Capital Management
Texas
$2.37M -$132K -2,310 -5%
AI
53
Axiom Investors
Connecticut
$2.1M – – –
Geode Capital Management
54
Geode Capital Management
Massachusetts
$2.08M +$455K +7,982 +29%
SGH
55
Sivik Global Healthcare
Connecticut
$2.06M +$1.99M +35,000 New
Swiss National Bank
56
Swiss National Bank
Switzerland
$1.93M +$1.87M +32,800 New
Bank of New York Mellon
57
Bank of New York Mellon
New York
$1.83M +$531K +9,326 +43%
Robeco Institutional Asset Management
58
Robeco Institutional Asset Management
Netherlands
$1.82M +$1.77M +31,012 New
USAA
59
United Services Automobile Association
Texas
$1.59M +$41.8K +733 +3%
FAAS
60
First Allied Advisory Services
California
$1.43M -$1.97M -34,665 -59%
State Street
61
State Street
Massachusetts
$1.42M +$1.37M +24,133 New
Northern Trust
62
Northern Trust
Illinois
$1.42M +$469K +8,241 +52%
CCS
63
Crosspoint Capital Strategies
California
$1.4M +$1.35M +23,773 New
EVM
64
Eaton Vance Management
Massachusetts
$1.2M +$1.16M +20,413 New
ProShare Advisors
65
ProShare Advisors
Maryland
$1.17M -$82.4K -1,447 -7%
TAM
66
Tocqueville Asset Management
New York
$1.16M +$754K +13,235 +204%
HighTower Advisors
67
HighTower Advisors
Illinois
$1.14M +$1.11M +19,441 New
EGI
68
EAM Global Investors
California
$1.1M -$293K -5,135 -22%
OCM
69
Orser Capital Management
Texas
$1.1M +$962K +16,880 New
LSA
70
L & S Advisors
California
$1.07M +$1.04M +18,285 New
CIAS
71
Capital Investment Advisory Services
North Carolina
$1.06M +$217K +3,803 +27%
California Public Employees Retirement System
72
California Public Employees Retirement System
California
$1.05M +$1.01M +17,794 New
Barclays
73
Barclays
United Kingdom
$985K +$61K +1,071 +7%
William Blair & Company
74
William Blair & Company
Illinois
$922K +$11.3K +198 +1%
DADC
75
D.A. Davidson & Co
Montana
$896K -$57 -1 -0%
1 2
3
4 5

CRSP Hedge Fund Activity: Q2 2018 in Review

174 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q2 2018, worth a combined $1.09B — up 27% from $855M a quarter earlier.

Buyers outnumbered sellers: 70 funds opened new CRSP positions and 30 closed out — a net gain of 40 holders — while 52 added to existing stakes and 32 trimmed.

The largest buyer was Federated Hermes, opening a new position worth an estimated $36M. The largest seller was NEA Management Company, cutting an estimated $79.4M.

  • 174 institutional investors held CRISPR Therapeutics (CRSP) as of Q2 2018, up from 135 in Q1 2018.
  • Funds reported $1.09B of CRISPR Therapeutics stock for Q2 2018, up 27% quarter-over-quarter.
  • 70 funds opened new CRISPR Therapeutics positions in Q2 2018 and 30 closed out, a net change of +40 holders.
  • The largest CRISPR Therapeutics buyer in Q2 2018 was Federated Hermes, an estimated $36M added.
  • The largest CRISPR Therapeutics seller in Q2 2018 was NEA Management Company, an estimated $79.4M sold.

Based on aggregated 13F filings for Q2 2018.